Spotlight: Inflation Reduction Act
Welcome to The Evidence Base Spotlight on the ‘Inflation Reduction Act’. Signed into law in August 2022 by the Biden-Harris Administration, the Inflation Reduction Act aims to lower healthcare costs and prescription drug prices for millions of Medicare beneficiaries across the US. In this Spotlight, we will be featuring expert insights, news, articles and more to help our readers stay up-to-date with the latest discussions and developments surrounding implementation of the Inflation Reduction Act and its implications for our community.
Read all related content here.
View our Infographic
Infographic: Inflation Reduction Act in numbers
Find a snapshot of the Inflation Reduction Act in this infographic that summarizes the key elements, including the timeline for implementation and the list of medicines expected to be subject to price negotiation in 2026.
Watch our recent Video Interviews, as part of our Patti’s People series:
Patti’s People – Patti Peeples speaks with Mark McClellan
In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Mark McClellan (Director of Robert J. Margolis Center and Professor of Business, Medicine, and Policy, Duke-Margolis Center for Health Policy). Mark discusses the impact of the Inflation Reduction Act on real-world evidence and affect the recent class action lawsuits may have on the roll out of the IRA and its implementation.
Patti’s People – Patti Peeples speaks with Kimberly Westrich
Patti Peeples of the The Peeples Collaborative talks with Kimberly Westrich, Chief Strategy Officer, National Pharmaceutical Council (NPC) about value assessment in the US, how ICER’s work is informing the CMS approach to Medicare drug price negotiations and the idea of CMS becoming a national HTA body in the country.
Read our Expert Insight interviews here:
Impact of the Inflation Reduction Act on real-world evidence: an interview with Amanda Cole, Office of Health Economics
Impact of the Inflation Reduction Act on drug development and patients: an interview with Jason Spangler, Innovation and Value Initiative
Impact of the Inflation Reduction Act on US health care: an interview with Corey Ford and Kimberly Westrich, Xcenda
Read our Editorials and Guest Columns here:
Trust, transparency, affordability: engaging patients for fair IRA drug pricing
First drugs selected for Medicare drug pricing negotiation: reactions, speculation and comments
The Inflation Reduction Act in numbers: impact on the development of small molecule medicines
The Inflation Reduction Act in numbers: estimating the impact of implementing Medicare drug pricing policies on the US healthcare ecosystem
The Inflation Reduction Act in numbers: HHS predicts savings for more than 18 million people in 2025
ISPOR 2023 – inside the first plenary: affordability, value and the role of the HEOR community
Public reactions to the revised Medicare drug pricing provisions in the Inflation Reduction Act
Get in touch to discuss the opportunities available to share your expertise, contribute to this theme or to become a theme sponsor.
